CARA - Cara Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue863,8033,177
Cost of Revenue---
Gross Profit863,8033,177
Operating Expenses
Research Development49,25321,22115,068
Selling General and Administrative9,2337,7706,181
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-58,400-25,188-18,072
Income from Continuing Operations
Total Other Income/Expenses Net652101126
Earnings Before Interest and Taxes-57,748-25,087-17,946
Interest Expense---
Income Before Tax-57,748-25,087-17,946
Income Tax Expense-468-397-201
Minority Interest---
Net Income From Continuing Ops-57,280-24,690-17,745
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-57,280-24,690-17,745
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-57,280-24,690-17,745